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Introduction
Nilotinib is a more potent and selective inhibitor of BCR-
ABL than imatinib.1 Results of the Evaluating Nilotinib
Efficacy and Safety in Clinical Trials-Newly Diagnosed
Patients (ENESTnd) phase III trial demonstrated the superior
efficacy of nilotinib compared with imatinib. After 1, 2 and
3 years of follow up, patients treated with nilotinib 300 mg
twice daily or nilotinib 400 mg twice daily had significantly
lower rates of progression to accelerated phase/blast crisis
(AP/BC) and fewer deaths, as well as significantly higher
molecular and cytogenetic response rates, compared with
patients receiving imatinib.2-4 Nilotinib is approved for the
treatment of patients with newly diagnosed Philadelphia
chromosome positive (Ph+) chronic myeloid leukemia in
chronic phase (CML-CP) and for the treatment of imatinib-
resistant or -intolerant adult patients with Ph+ CML in CP or
AP.5,6
Despite the positive impact of tyrosine kinase inhibitors
(TKIs) such as nilotinib and imatinib on the treatment of
CML, some patients do not achieve optimal responses to TKI
therapy. Patients who experience treatment failure on TKI
therapy are unlikely to achieve long-term disease control and
are at high risk of disease progression; patients with subopti-
mal responses to TKI therapy have a reduced likelihood of
achieving future optimal responses and outcomes compared
with patients who achieve optimal responses to therapy.7-9
Thus, careful management of patients with CML-CP who
have non-optimal responses to front-line TKI therapy is nec-
essary.
For patients who experience treatment failure on TKI ther-
apy, the European LeukemiaNet recommends switching to a
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In a randomized, phase III trial of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromo-
some positive chronic myeloid leukemia in chronic phase, more patients had suboptimal response or treatment
failure on front-line imatinib than on nilotinib. Patients with suboptimal response/treatment failure on imatinib
400 mg once or twice daily or nilotinib 300 mg twice daily could enter an extension study to receive nilotinib 400
mg twice daily. After a 19-month median follow up, the safety profile of nilotinib 400 mg twice daily in patients
switching from imatinib (n=35) was consistent with previous reports, and few new adverse events occurred in
patients escalating from nilotinib 300 mg twice daily (n=19). Of patients previously treated with imatinib or nilo-
tinib 300 mg twice daily, respectively, 15 of 26 (58%) and 2 of 6 (33%) without complete cytogenetic response at
extension study entry, and 11 of 34 (32%) and 7 of 18 (39%) without major molecular response at extension study
entry, achieved these responses at any time on nilotinib 400 mg twice daily. Estimated 18-month rates of freedom
from progression and overall survival after entering the extension study were lower for patients switched from
imatinib (85% and 87%, respectively) versus nilotinib 300 mg twice daily (95% and 94%, respectively). Nilotinib
dose escalation was generally well tolerated and improved responses in about one-third of patients with subopti-
mal response/treatment failure. Switch to nilotinib improved responses in some patients with suboptimal
response/treatment failure on imatinib, but many did not achieve complete cytogenetic response (clinicaltrials.gov
identifiers:00718263, 00471497 - extension).
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ABSTRACT
different therapy “whenever available and applicable”.8
However, for patients with suboptimal responses, who
may continue to derive benefit from their current treat-
ment, the decision for clinicians is less clear.10 Several stud-
ies have shown that imatinib dose escalation may provide
additional benefit in some patients with suboptimal
responses /treatment failure on standard-dose imatinib;11-13
however, high-dose imatinib is associated with an
increased risk of adverse events (AEs), particularly grade
3/4 hematologic toxicity.14,15 The safety and efficacy of
nilotinib in patients with imatinib-resistant or -intolerant
CML are well established.16-20 However, prospective clini-
cal data evaluating the benefits of switching patients with
suboptimal response on front-line imatinib to nilotinib are
limited.19,21 Furthermore, the impact of nilotinib dose esca-
lation in patients with suboptimal responses/treatment
failure on frontline nilotinib has yet to be explored.
An extension study to ENESTnd was designed to pro-
vide patients who experienced suboptimal responses or
treatment failure on front-line imatinib or nilotinib in the
core study the opportunity to receive other treatment
options. This report describes the frequency of suboptimal
responses/treatment failure in newly diagnosed CML-CP
patients treated with imatinib, nilotinib 300 mg twice
daily, or nilotinib 400 mg twice daily in the ENESTnd core
study. It also presents the first results of the ENESTnd
extension study, including the safety and efficacy of nilo-
tinib 400 mg twice daily in patients with suboptimal
responses/treatment failure on front-line imatinib or nilo-
tinib 300 mg twice daily, with a median follow up of 19
months.
Methods
ENESTnd core study
The design of ENESTnd has been previously reported2-4 and is
described in the Online Supplementary Appendix. Patients with sub-
optimal response or treatment failure in the core study were eligi-
ble for the extension study. Definitions of suboptimal response
and treatment failure were based on those in the 2009 European
LeukemiaNet recommendations8 and are described in the Online
Supplementary Methods. Patients who were intolerant of imatinib
or nilotinib in the core study were ineligible for the extension
study. 
ENESTnd extension study: patients, study design and
treatments
Patients with suboptimal response or treatment failure on ima-
tinib (400 mg once or twice daily) or nilotinib 300 mg twice daily
in the core study received nilotinib 400 mg twice daily in the
extension study. Patients with treatment failure on nilotinib 400
mg twice daily in the core study received imatinib 400 mg twice
daily in the extension study. Dose reductions of nilotinib or ima-
tinib were allowed for patients who experienced treatment-relat-
ed toxicity. Patients could be withdrawn from the extension study
for the following reasons: death, intolerable toxicity, disease pro-
gression, or patient’s or investigator’s decision. Survival informa-
tion and progression events in patients who discontinued were
collected every three months (1 month=28 days) for up to ten
years.  
End points
The primary objective of the extension study was to character-
ize the safety and tolerability of nilotinib 400 mg twice daily after
insufficient response to imatinib or nilotinib 300 mg twice daily in
the core study. The secondary objective was to evaluate the effi-
cacy of nilotinib 400 mg twice daily after insufficient response to
imatinib or nilotinib 300 mg twice daily. Molecular response was
assessed in all patients by real-time quantitative reverse transcrip-
tase polymerase chain reaction (RQ-PCR) every month for the first
three months and every three months thereafter in a central labo-
ratory (MolecularMD, Portland, OR, USA). Other study defini-
tions and assessments were as defined previously for the
ENESTnd core study.2-4
Statistical analysis
Incidence of suboptimal response and treatment failure in the
ENESTnd core study was analyzed descriptively by treatment
arm. Safety and efficacy data from the ENESTnd extension study
were analyzed descriptively according to original core study treat-
ment arm. Rates of complete cytogenetic response (CCyR) and
major molecular response (MMR) at any time during the extension
study (from time of entry to time of data cut off) and rates of
MMR by 12 months were determined according to response at
time of extension study entry. Time-to-event outcomes were ana-
lyzed using the Kaplan-Meier method.
The cut-off date for all analyses was July 27, 2011 (the same cut-
off date as for the 3-year analysis of the ENESTnd core study4).
The ENESTnd core and extension studies are being conducted
according to the ethical principles of the Declaration of Helsinki,
and written informed consent was obtained from each patient.
The study protocols and amendments were approved by the insti-
tutional review board, independent ethics committee, or research
ethics board at each center. These studies are registered at
www.clinicaltrials.gov (clinicaltrials.gov identifiers:00718263, 00471497
- extension).
Results
ENESTnd core study: incidence of suboptimal
response/treatment failure
The ENESTnd core study enrolled 846 patients with
newly diagnosed CML-CP, randomized to nilotinib 300
mg twice daily (n=282), nilotinib 400 mg twice daily
(n=281), or imatinib 400 mg once daily (n=283). The inci-
dence of suboptimal response by 6, 12 and 18 months was
lower in each nilotinib arm than in the imatinib arm
(Figure 1A). By 6 months, 6 (2%), 7 (2%), and 18 (6%)
patients in the nilotinib 300 mg twice-daily, nilotinib 400
mg twice-daily, and imatinib arms, respectively, had sub-
optimal response. By 12 months, 11 (4%), 12 (4%), and 38
(13%) patients in the nilotinib 300 mg twice-daily, nilo-
tinib 400 mg twice-daily, and imatinib arms, respectively,
had suboptimal response. The incidence of suboptimal
response by 18 months (when a lack of MMR first became
a criterion for suboptimal response) was higher across all
3 treatment arms, and the difference between the nilotinib
arms and the imatinib arm persisted, with suboptimal
response in 68 (24%), 84 (30%), and 128 (45%) patients in
the nilotinib 300 mg twice-daily, nilotinib 400 mg twice-
daily, and imatinib arms, respectively. Similarly, fewer
nilotinib-treated patients than imatinib-treated patients
had treatment failure by 6, 12, and 18 months (Figure 1B). 
When responses were evaluated in patients stratified by
Sokal risk score, rates of suboptimal response and treat-
ment failure were generally lower in nilotinib-treated
patients than in imatinib-treated patients, regardless of
Sokal risk (Table 1). The differences in rates of treatment
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failure between the nilotinib arms and the imatinib arm
were greatest in high Sokal risk patients; rates of treatment
failure by 12 and 18 months were 6% and 8%, 4% and
4%, and 22% and 28% in the nilotinib 300 mg twice-
daily, nilotinib 400 mg twice-daily, and imatinib arms,
respectively.
Patients with suboptimal response or treatment failure
on imatinib 400 mg once daily were permitted to dose
escalate to imatinib 400 mg twice daily. However, as has
been previously reported,22 over half of these patients did
not achieve improved responses following imatinib dose
escalation, and many required subsequent dose reductions
or interruptions.   
ENESTnd extension study: patients, treatments, and
disposition
In the ENESTnd core study, 57 patients discontinued
from the imatinib arm due to suboptimal response or
treatment failure; 35 of these patients entered the exten-
sion study to receive nilotinib 400 mg twice daily (Table
2). Many of these patients (24 of 35; 69%) had dose-esca-
lated to imatinib 400 mg twice daily while on the core
study. The majority of patients entering the extension
study from the imatinib arm had treatment failure in the
core study (60%; 21 of 35), 34% (12 of 35) had suboptimal
response, and 6% (2 of 35) entered the extension study
based on the investigator’s assessment without meeting
the criteria for suboptimal response/treatment failure. In
the nilotinib 300 mg twice-daily arm of the core study, 28
patients discontinued due to suboptimal response or treat-
ment failure, and 19 of these patients entered the exten-
sion study to receive nilotinib 400 mg twice daily. The
majority of patients entering the extension study from the
nilotinib 300 mg twice daily arm had suboptimal response
in the core study (79%; 15 of 19), 16% (3 of 19) had treat-
ment failure, and 5% (1 patient) entered the extension
study based on the investigator’s assessment without
meeting the criteria for suboptimal response/treatment
failure.
With a median follow up of 19 months in the extension
study, 63% (22 of 35) of patients previously treated with
imatinib and 74% (14 of 19) of patients previously treated
with nilotinib 300 mg twice daily remained on extension
treatment with nilotinib 400 mg twice daily at the time of
data cut off. In patients previously treated with imatinib,
the median time on extension treatment was 15.5 months
(range 0.2-35.2 months), and the median dose intensity
was 799 mg/day (range 421-800 mg/day); 17 patients
(49%) experienced a dose reduction or interruption
because of an AE or laboratory abnormality. Of patients
previously treated with imatinib, 13 discontinued exten-
sion treatment for the following reasons: unsatisfactory
therapeutic effect (n=5), AEs or laboratory abnormalities
(n=4), disease progression (n=2), death (n=1), and protocol
deviation (n=1). In patients previously treated with nilo-
tinib 300 mg twice daily, the median time on extension
treatment was 18.0 months (range 1.0-25.5 months), and
the median dose intensity was 800 mg/day (range 605-800
mg/day); 4 patients (21%) experienced a dose reduction or
interruption because of an AE or laboratory abnormality.
Of patients previously treated with nilotinib 300 mg twice
daily, 5 discontinued extension treatment (4 due to unsat-
isfactory therapeutic effect and 1 due to protocol devia-
tion). 
A total of 11 patients in the core study discontinued
nilotinib 400 mg twice daily due to treatment failure, and
3 of these patients entered the extension study to receive
imatinib 400 mg twice daily. Given the limited number of
patients receiving imatinib 400 mg twice daily in the
extension study, analysis of imatinib safety and efficacy in
these patients was not performed. 
Safety of nilotinib 400 mg twice daily in the extension
study
In patients previously treated with imatinib, the safety
profile of nilotinib 400 mg twice daily was consistent with
that in previous reports of patients who switched from
imatinib to nilotinib.16,19,20 Nineteen patients (54%) experi-
enced grade 3/4 AEs, and 4 patients (11%) discontinued
treatment because of AEs. The most common non-hema-
tologic AEs of any grade were rash (29%), headache
(23%), and dyspnea (17%) (Table 3). Grade 3/4 non-hema-
tologic AEs were uncommon. Grade 3/4 anemia (9%),
neutropenia (9%), and thrombocytopenia (6%) occurred
infrequently. The most common (occurring in at least 2
patients) grade 3/4 biochemical abnormalities were hyper-
bilirubinemia in 3 patients (9%), hyperglycemia in 2
patients (6%), and decreased phosphorus in 2 patients
(6%). In patients previously treated with nilotinib 300 mg
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Figure 1. Cumulative incidence of suboptimal response (A) and treat-
ment failure (B) in the ENESTnd core study by 6, 12, and 18 months.
Key criteria for suboptimal response/treatment failure at 6, 12, and
18 months are shown in parentheses on the x-axis. Suboptimal
response also included loss of major molecular response (MMR) at
any time. Treatment failure also included loss of complete hemato-
logic response (CHR), loss of partial cytogenetic response/complete
cytogenetic response (PCyR/CCyR), or progression to accelerated
phase/blast crisis at any time. Patients satisfying criteria for both
suboptimal response and treatment failure were considered to have
treatment failure. Only a patient’s worst response at or before each
time point was counted.
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twice daily, there were minimal changes in safety from
those reported with nilotinib 300 mg twice daily in the
ENESTnd core study.2-4 Six patients (32%) had grade 3/4
AEs, and no patient discontinued because of AEs or labo-
ratory abnormalities. There were no grade 3/4 myelosup-
pression events and few newly occurring or worsening
grade 3/4 biochemical abnormalities (Table 3). 
Efficacy of nilotinib 400 mg twice daily in the 
extension study
Many patients with suboptimal response/treatment fail-
ure on front-line imatinib achieved improved cytogenetic
and molecular responses after switching to nilotinib 400
mg twice daily. Analysis of CCyR and MMR rates in
patients previously treated with imatinib excluded 9 and
one patients, respectively, who had these responses at
extension study entry. Of the 26 patients previously treat-
ed with imatinib who did not have CCyR at extension
study entry, 15 (58%) achieved CCyR at any time (from
date of extension study entry to data cut-off date; median
follow up 19 months) on nilotinib 400 mg twice daily
(Figure 2A). Of the 34 patients previously treated with
imatinib who did not have MMR at extension study entry,
11 (32%) achieved MMR at any time on nilotinib 400 mg
twice daily. These same 11 patients all achieved MMR by
12 months, so the rate of MMR by 12 months was also
32%. Two of 8 patients (25%) without MMR but with
CCyR at extension study entry achieved MMR by 12
months.
Analysis of CCyR and MMR rates in patients previously
treated with nilotinib 300 mg BID excluded 13 and one
patients, respectively, who had these responses at exten-
sion study entry. In patients previously treated with nilo-
tinib 300 mg twice daily, 2 of 6 patients (33%) without
CCyR at extension study entry achieved CCyR at any
time on nilotinib 400 mg twice daily, and 7 of 18 patients
(39%) without MMR at extension study entry achieved
MMR at any time (Figure 2B). These same 7 patients all
achieved MMR by 12 months, so the rate of MMR by 12
months was also 39%. Five of 12 patients (42%) without
MMR but with CCyR at extension study entry achieved
MMR by 12 months.
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Table 1. Cumulative incidence of suboptimal response and treatment failure by 12 and 18 months in the ENESTnd Core Study stratified by Sokal
Risk Scorea.
Nilotinib Nilotinib Imatinib
300 mg Twice Daily 400 mg Twice Daily 400 mg Once Daily 
(n = 282) (n = 281) (n = 283)
12 months 18 months 12 months 18 months 12 months 18 months
Sokal Score n (%) n (%) n (%) n (%) n (%) n (%)
Low n=103 n=103 n=104
Suboptimal response 1 (1) 21 (20) 1 (1) 26 (25) 11 (11) 54 (52)
Treatment failure 2 (2) 5 (5) 1 (1) 1 (1) 6 (6) 7 (7)
Intermediate n=101 n=100 n=101
Suboptimal response 6 (6) 27 (27) 6 (6) 27 (27) 12 (12) 44 (44)
Treatment failure 1 (1) 1 (1) 1 (1) 6 (6) 7 (7) 15 (15)
High n=78 n=78 n=78
Suboptimal response 4 (5) 20 (26) 9 (12) 31 (40) 15 (19) 30 (38)
Treatment failure 5 (6) 6 (8) 3 (4) 3 (4) 17 (22) 22 (28)
aPatients satisfying criteria for more than 1 category were only counted once under the worst category (with treatment failure worse than suboptimal response and suboptimal
response worse than optimal response).
Table 2. ENESTnd Core Study: reasons for entry into the ENESTnd Extension Studya.
Imatinib Nilotinib 300 mg Twice Daily 
(n = 283) (n = 282)
Total With Dose Without Dose 
Escalation to 400 mg Escalation
Twice Daily
Patients, n 283 94 189 282
Discontinued core study due to suboptimal response/treatment failure, n.
Total 57 32 25 28
Suboptimal response 22 12 10 16
Treatment failure 33 19 14 9
Otherb 2 1 1 3
Entered extension study due to suboptimal response/treatment failure, n.
Total 35 24 11 19
Suboptimal response 12 8 4 15
Treatment failure 21 15 6 3
Otherb 2 1 1 1
aPatients from the nilotinib 300-mg twice-daily and imatinib arms of the ENESTnd core study received nilotinib 400 mg twice daily in the extension study. Three patients who dis-
continued from the nilotinib 400-mg twice-daily arm of the core study because of treatment failure entered the extension study to receive imatinib 400 mg twice daily.
bDiscontinued/entered study per investigator’s assessment without satisfying the criteria for suboptimal response/treatment failure.
Molecular responses were achieved in the extension
study in patients of all Sokal risk groups (Table 4). Among
patients previously treated with imatinib without MMR at
extension study entry, 4 of 8 (50%) low Sokal risk
patients, 4 of 9 (44%) intermediate-risk patients, and 3 of
17 (18%) high-risk patients achieved MMR or better at
any time on nilotinib 400 mg twice daily. Of the 11
patients with high Sokal risk and treatment failure on pre-
vious imatinib, 2 (18%) had a molecular response on
extension treatment (1 achieved MR4, 1 achieved MR45).
Among patients previously treated with nilotinib 300 mg
twice daily without MMR at extension study entry, one of
4 (25%) low Sokal risk patients, 4 of 6 (67%) intermediate-
risk patients, and 2 of 8 (25%) high-risk patients achieved
MMR or better at any time on nilotinib 400 mg twice
daily.
The estimated rates of freedom from progression to
AP/BC at 18 months from start of extension treatment
were 85% (95%CI: 71-99%) and 95% (95%CI: 85-100%)
in patients previously treated with imatinib and with nilo-
tinib 300 mg twice daily, respectively. In total, 5 patients
previously treated with imatinib who switched to nilo-
tinib on the extension study progressed to AP/BC: 2 pro-
gressed during extension treatment and 3 progressed after
discontinuation of extension treatment. Additionally, one
patient previously treated with nilotinib 300 mg twice
daily progressed to AP/BC after discontinuation of the
extension treatment. All progression events reported here
were also included in the overall reported progression
events from the ENESTnd core study with three years of
follow up.4
The estimated rates of overall survival at 18 months
from the start of extension treatment were 87% (95%CI,
75-99%) and 94% (95%CI, 83%-100%) in patients previ-
ously treated with imatinib and with nilotinib 300 mg
twice daily, respectively.  Seven patients previously treat-
ed with imatinib died on the extension study: 5 from
CML-related causes at 2, 246, 286, 326, and 593 days after
treatment discontinuation, 1 from chronic renal failure 91
days after treatment discontinuation, and 1 from pneumo-
nia 788 days after treatment discontinuation. One patient
previously treated with nilotinib 300 mg twice daily died
305 days after treatment discontinuation due to CML-
related complications. All deaths reported here were also
included in the overall deaths reported in the ENESTnd
core study with 3 years of follow up.4
Discussion
In the ENESTnd core study, rates of suboptimal
response and treatment failure by 6, 12, and 18 months
were lower in patients treated with front-line nilotinib
than in patients treated with front-line imatinib.
Strikingly, the rate of treatment failure by 18 months was
nearly 4 times higher in the imatinib arm than in the nilo-
tinib arms. This difference was most pronounced among
high Sokal risk patients, who had a high rate of treatment
failure on imatinib but who fared similarly to patients
with low or intermediate Sokal risk when treated with
nilotinib. This may be because the increased potency and
selectivity of nilotinib can more effectively compensate
for unfavorable host factors than imatinib. These results
are consistent with previously reported efficacy data
demonstrating numerically higher rates of CCyR, MMR,
and deep molecular response (i.e. MR4 (BCR-ABLIS 
≤ 0.01%) and MR4.5 (BCR-ABLIS ≤ 0.0032%)23 with nilo-
tinib versus imatinib in all Sokal risk groups.3,4
Results from the ENESTnd extension study demonstrate
that many patients with suboptimal response or treatment
failure on imatinib may benefit from switching to nilo-
tinib. More than half of patients who did not achieve
CCyR on imatinib core treatment achieved this response
on nilotinib 400 mg twice daily, and over 30% of patients
who did not achieve MMR on imatinib core treatment
achieved this response with nilotinib 400 mg twice daily.
Safety and efficacy results observed in this study were
consistent with those in previous reports of second-line
nilotinib treatment in patients with imatinib-resistant or 
-intolerant CML-CP.16,19,20
Rates of suboptimal response and treatment failure with
front-line nilotinib 300 mg twice daily and nilotinib 400
mg twice daily in the ENESTnd core study were similar,
yet for patients with suboptimal response or treatment
failure on nilotinib 300 mg twice daily, dose escalation to
nilotinib 400 mg twice daily provided additional efficacy
benefit in approximately one-third of patients (33% of
patients who did not achieve CCyR on nilotinib 300 mg
twice daily core treatment achieved this response on nilo-
tinib 400 mg twice daily, and 39% of patients who did not
achieve MMR on nilotinib 300 mg twice daily core treat-
ment achieved this response on nilotinib 400 mg twice
daily). Dose escalation of nilotinib was safe, with few new
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Figure 2. Cumulative incidence of complete cytogenetic response
(CCyR) and major molecular response (MMR) on extension study
treatment (nilotinib 400 mg twice daily) in patients previously treated
with (A) imatinib or (B) nilotinib 300 mg twice daily. Shown from left
to right are rates of CCyR at any time (from date of extension study
entry to data cut-off date; median follow up of 19 months) in patients
without CCyR at extension study entry, rates of MMR at any time and
by 12 months in patients without MMR at extension study entry, and
rates of MMR by 12 months in patients without MMR but with CCyR
at extension study entry.
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AEs observed, and may represent a viable treatment strat-
egy in patients with suboptimal response or treatment fail-
ure on front-line nilotinib 300 mg twice daily. However, it
remains unknown whether dose escalation of nilotinib in
such patients is preferable to alternate therapies, including
other TKIs and stem cell transplantation. 
Responses of MMR or better were observed on nilotinib
400 mg twice daily both in patients with suboptimal
response and in patients with treatment failure on front-
line imatinib across all Sokal risk groups (including 2
patients with treatment failure on imatinib who went on
to achieve deep molecular responses on nilotinib 400 mg
twice daily), suggesting that a switch to nilotinib 400 mg
twice daily is a reasonable strategy in patients of any Sokal
risk category. However, this switch in therapy is not effec-
tive in all patients. Many patients with suboptimal
response/treatment failure on previous imatinib in our
study did not achieve improved responses on extension
treatment; such patients may be candidates for treatment
with an alternate TKI or stem cell transplantation. 
Notably, although all patients in the extension study
received the same treatment of nilotinib 400 mg twice
daily, the estimated 18-month rates of freedom from pro-
gression and overall survival were lower for patients
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Table 3. Most frequently reported (≥ 10%) adverse events and newly occurring or worsening hematologic and biochemical abnormalities in
patients treated with nilotinib 400 mg twice daily in the ENESTnd Extension Study by previous therapy, regardless of relationship to study druga.
Event, n. (%)                                                               Nilotinib 400 mg Twice Daily
                                                                                       Previous Imatinibb                                                       Previous Nilotinib
                                                                                               (n = 35)                                                             300 mg Twice Dailyc       
Adverse Events                                                                                                                                                       (n = 19)
                                                                          Any Grade                        Grade 3/4                        Any Grade                             Grade 3/4
Rash                                                                                     10 (29)                                     1 (3)                                      3 (16)                                                0
Headache                                                                            8 (23)                                          0                                          2 (11)                                                0
Dyspnea                                                                               6 (17)                                      1 (3)                                           0                                                     0
Insomnia                                                                             4 (11)                                          0                                          2 (11)                                                0
Diarrhea                                                                              4 (11)                                          0                                           1 (5)                                                 0
Nausea                                                                                 4 (11)                                          0                                               0                                                     0
Pyrexia                                                                                 4 (11)                                          0                                               0                                                     0
Pruritus                                                                                 3 (9)                                           0                                          4 (21)                                                0
Back pain                                                                              3 (9)                                       1 (3)                                      3 (16)                                                0
Arthralgia                                                                             3 (9)                                           0                                          2 (11)                                                0
Muscle spasms                                                                   1 (3)                                           0                                          2 (11)                                                0
Upper respiratory tract infection                                      0                                               0                                          3 (16)                                                0
Depressed mood                                                                   0                                               0                                          2 (11)                                                0
Dry skin                                                                                    0                                               0                                          2 (11)                                                0
Myocardial infarction                                                            0                                               0                                          2 (11)                                           2 (11)
Seasonal allergy                                                                     0                                               0                                          2 (11)                                                0
Hematologic abnormalities
Lymphopenia                                                                     18 (51)                                         0                                          7 (37)                                                0
Anemia                                                                                11 (31)                                     3 (9)                                       1 (5)                                                 0
Neutropenia                                                                      10 (29)                                     3 (9)                                      2 (11)                                                0
Thrombocytopenia                                                           10 (29)                                     2 (6)                                           0                                                     0
Leukopenia                                                                         8 (23)                                          0                                               0                                                     0
Biochemical abnormalities
ALT increased                                                                   26 (74)                                     1 (3)                                      6 (32)                                                0
Total bilirubin increased                                                19 (54)                                     3 (9)                                     10 (53)                                           1 (5)
AST increased                                                                   17 (49)                                     1 (3)                                      5 (26)                                                0
Glucose increased                                                           13 (37)                                     2 (6)                                      5 (26)                                             1 (5)
Phosphorus decreased                                                   11 (31)                                     2 (6)                                      4 (21)                                           2 (11)
Total cholesterol increased                                            8 (23)                                          0                                          2 (11)                                                0
Alkaline phosphatase increased                                    5 (14)                                          0                                               0                                                     0
Lipase increased                                                               4 (11)                                          0                                           1 (5)                                              1 (5)
Amylase increased                                                             3 (9)                                           0                                          2 (11)                                                0
Prothrombin time increased                                          1 (3)                                           0                                          3 (16)                                             1 (5)
ALT: alanine aminotransferase; AST: aspartate aminotransferase. aSafety of imatinib 400 mg twice daily in the 3 patients who received imatinib in the extension study after failure of
nilotinib 400 mg twice daily in the core study was not analyzed. bPatients previously treated with imatinib 400 mg once daily (with or without dose escalation to imatinib 400 mg
twice daily) in the ENESTnd core study who received nilotinib 400 mg twice daily in the extension study. cPatients previously treated with nilotinib 300 mg twice daily in the ENESTnd
core study who received nilotinib 400 mg twice daily in the extension study.
switched from imatinib (85% and 87%, respectively) than
for those initially treated with nilotinib 300 mg twice daily
(95% and 94%, respectively). In addition, opposing trends
in response rates between the two groups were observed,
with higher rates of CCyR achievement on nilotinib 400
mg twice daily in patients previously treated with ima-
tinib, and higher rates of MMR achievement in patients
previously treated with nilotinib 300 mg twice daily
(Figure 2). These differences in outcomes could be related
to the higher proportion of patients in this study who
switched from imatinib due to treatment failure versus
suboptimal response; in contrast, most patients from the
nilotinib 300 mg twice-daily arm entered the extension
study due to suboptimal response. Very few patients
entered the extension study having not achieved a CCyR
on nilotinib 300 mg twice daily, and the relatively low rate
of CCyR achievement in these patients on nilotinib dose
escalation may be an indication of more aggressive disease
biology. Nonetheless, the increased risk of disease pro-
gression or death in patients with suboptimal
response/treatment failure on front-line imatinib, despite a
subsequent switch to nilotinib, highlights the importance
of optimal front-line therapy selection, in order to achieve
and sustain the best possible responses early in a patient’s
treatment course.
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Table 4. Best molecular response on nilotinib 400 mg twice daily extension treatment at any timea according to Sokal risk and reason for dis-
continuation of core treatment in patients without MMR at extension study entry.
Previous imatinib discontinued Previous nilotinib 300 mg twice 
due to: daily discontinued due to:
Best molecular response on Suboptimal Treatment Other Suboptimal Treatment Other
extension treatment Response Failure Response Failure n = 0
Low risk n=6 n=2 n=0 n=3 n=1
Less than MMR, n (%) 3 (50) 1 (50) 2 (67) 1 (100)
MMR, n (%) 2 (33) 0 1 (33) 0
MR4, n (%) 0 1 (50) 0 0
MR4.5, n (%) 1 (17) 0 0 0
Intermediate risk n=2 n=7 n=0 n=6 n = 0 n = 0 
Less than MMR, n (%) 1 (50) 3 (43) 2 (33)
MMR, n (%) 1 (50) 3 (43) 4 (67)
MR4, n (%) 0 0 0
MR4.5, n (%) 0 0 0
Missingb, n (%) 0 1 (14) 0
High risk n=4 n=11 n=2 n=5 n=2 n = 1
Less than MMR, n (%) 4 (100) 9 (82) 1 (50) 4 (80) 1 (50) 1 (100)
MMR, n (%) 0 0 1 (50) 1 (20) 0 0
MR4, n (%) 0 1 (9) 0 0 0 0
MR4.5, n (%) 0 1 (9) 0 0 1 (50) 0
MMR: major molecular response (BCR-ABLIS ≤ 0.1%); MR4 BCR-ABLIS ≤ 0.01%; MR4.5, BCR-ABLIS ≤ 0.0032%. aBased on a median follow up of 19 months (from date of extension
study entry to data cutoff date). bIf the number of ABL transcripts was < 3000, BCR-ABL ratios were considered missing.
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